Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834638 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
NCT01834638 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 268 participants.
The verdict
NCT01834638, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
Study Summary
This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).
Interventions
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834638
The ClinicalTrials.gov registry entry for NCT01834638 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-126 is the first listed.
NCT01834638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834638 about?
NCT01834638 is a clinical study titled "Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)". This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).
What is the current status of trial NCT01834638?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2013-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01834638?
The interventions under investigation include: ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01834638?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.